Study of the Safety of QRH-882260 Heptapeptide

Completed · Phase 1

Conditions studied: Healthy Adults

In brief

The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).

Key facts

Study ID

NCT02574858

Run by

University of Michigan

People needed

25

Starts

2015-11-01

Expected to finish

2016-08-01

Last updated by the study team

2018-01-02

Who can join

Age: 25 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults age 25 to 100 years
• Not pregnant (willing to have pregnancy test if applicable)
• No recent illness (infection, URI, virus or flu) within 2 weeks,
• Stable health status (i.e. no medication changes within 2 months, no recent surgery, etc. per PI)
• Willing and able to sign informed consent
• Willing and able to drink the peptide and a tap water chaser
• Willing and able to get baseline and 24-48 hours post ingestion labs Exclusion Criteria
• Known allergy to Cy5 or derivatives, such as indocyanine green (ICG)
• Subjects on active chemotherapy or radiation therapy
• Diabetics on insulin/hypoglycemic (due to fasting requirements)

Where it is running

• University of Michigan Hospital — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.